Squarepoint
SLN icon

Squarepoint’s Silence Therapeutics SLN Stock Holding History

Squarepoint’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
115,918
+26,449
+30% +$186K ﹤0.01% 2711
2026
Q1 		$472K Buy
+89,469
New +$493K ﹤0.01% 3372

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Squarepoint's SLN Position: Q2 2026 in Review

Squarepoint increased its Silence Therapeutics (SLN) stake by 30% in Q2 2026, buying an estimated $186K and bringing the position to 115,918 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Squarepoint first reported a position in SLN in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Squarepoint held 115,918 shares of Silence Therapeutics worth $1.27M as of Q2 2026.
  • Squarepoint bought 26,449 Silence Therapeutics shares in Q2 2026, an estimated $186K.
  • Silence Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2711 holding.
  • Squarepoint first reported a position in Silence Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.